HIV Treatment Guidelines Give Kaletra Timely Boost As Reyataz Launches
Executive Summary
HHS' revised guidelines for HIV treatment give Abbott's Kaletra a timely endorsement as Bristol-Myers Squibb is launching its competing protease inhibitor Reyataz
You may also be interested in...
GSK/Vertex Lexiva Clears FDA With Food-Free Dosing, Broad Indication
GlaxoSmithKline will likely focus on the dosing flexibility of Lexiva (fosamprenavir), including the option to take with or without food, in its marketing of the protease inhibitor
GSK/Vertex Lexiva Clears FDA With Food-Free Dosing, Broad Indication
GlaxoSmithKline will likely focus on the dosing flexibility of Lexiva (fosamprenavir), including the option to take with or without food, in its marketing of the protease inhibitor
Bristol Reyataz To Launch In July; Lipid Data Included In Labeling
Bristol-Myers Squibb will make Reyataz (atazanavir) available in July following the June 20 approval of the HIV treatment